THERATECHNOLOGIES INC. news, videos and press releases
For more news please use our advanced search feature.
THERATECHNOLOGIES INC. - More news...
THERATECHNOLOGIES INC. - More news...
- Theratechnologies Reports Financial Results for the Second Quarter 2025
- Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
- Theratechnologies Reports on its Annual Meeting of Shareholders
- Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
- Theratechnologies Resumes Distribution of EGRIFTA SV®
- Theratechnologies Provides Update on EGRIFTA SV® Supply
- Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
- Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
- Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
- Theratechnologies Announces Resumed Production of EGRIFTA SV®
- Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
- Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
- Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
- Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
- Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
- Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
- Theratechnologies Reports on its Annual Meeting of Shareholders
- Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
- Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
- Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
- Theratechnologies Appoints Elina Tea to its Board of Directors
- Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
- Theratechnologies Announces Update on its Preclinical Oncology Research Program
- Theratechnologies Appoints Jordan Zwick to its Board of Directors
- Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
- Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
- Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
- Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
- Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
